{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:25:02Z","timestamp":1787505902823,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"none"},{"name":"None"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40272-025-00719-0","type":"journal-article","created":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T23:33:57Z","timestamp":1758497637000},"page":"723-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current Treatment Modalities for Urea Cycle Disorders"],"prefix":"10.1007","volume":"27","author":[{"given":"Nicholas","family":"Ah Mew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-2914","authenticated-orcid":false,"given":"Uta","family":"Lichter-Konecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"6","key":"719_CR1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41390-023-02722-y","volume":"94","author":"U Lichter-Konecki","year":"2023","unstructured":"Lichter-Konecki U, Sanz JH, McCarter R, Urea Cycle Disorders Consortium. Relationship between longitudinal changes in neuropsychological outcome and disease biomarkers in urea cycle disorders. Pediatr Res. 2023;94(6):2005\u201315.","journal-title":"Pediatr Res"},{"issue":"4","key":"719_CR2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/glia.20624","volume":"56","author":"U Lichter-Konecki","year":"2008","unstructured":"Lichter-Konecki U, Mangin JM, Gordish-Dressman H, Hoffman EP, Gallo V. Gene expression profiling of astrocytes from hyperammonemic mice reveals altered pathways for water and potassium homeostasis in vivo. Glia. 2008;56(4):365\u201377.","journal-title":"Glia"},{"issue":"22","key":"719_CR3","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMoa066596","volume":"356","author":"GM Enns","year":"2007","unstructured":"Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007;356(22):2282\u201392.","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"719_CR4","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1067\/mpd.2001.111836","volume":"138","author":"ML Batshaw","year":"2001","unstructured":"Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001;138(1 Suppl):S46\u201355.","journal-title":"J Pediatr"},{"issue":"2","key":"719_CR5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jpeds.2014.04.012","volume":"165","author":"N Ah Mew","year":"2014","unstructured":"Ah Mew N, McCarter R, Daikhin Y, Lichter-Konecki U, Nissim I, Yudkoff M, et al. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate. J Pediatr. 2014;165(2):401-3.e3.","journal-title":"J Pediatr"},{"key":"719_CR6","volume-title":"GeneReviews\u00ae","author":"U Lichter-Konecki","year":"1993","unstructured":"Lichter-Konecki U, Caldovic L, Morizono H, Simpson K, Ah Mew N, MacLeod E, et al. Ornithine transcarbamylase deficiency. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews\u00ae. Seattle: University of Washington; 1993."},{"issue":"4","key":"719_CR7","volume":"12","author":"K Sen","year":"2024","unstructured":"Sen K, Izem R, Long Y, Jiang J, Konczal LL, McCarter RJ, et al. Are asymptomatic carriers of OTC deficiency always asymptomatic? A multicentric retrospective study of risk using the UCDC longitudinal study database. Mol Genet Genomic Med. 2024;12(4):e2443.","journal-title":"Mol Genet Genomic Med"},{"issue":"6","key":"719_CR8","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/jimd.12772","volume":"47","author":"J Haberle","year":"2024","unstructured":"Haberle J. Citrin deficiency: the east-side story. J Inherit Metab Dis. 2024;47(6):1129\u201333.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"719_CR9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/jimd.12483","volume":"45","author":"J Kido","year":"2022","unstructured":"Kido J, Haberle J, Sugawara K, Tanaka T, Nagao M, Sawada T, et al. Clinical manifestation and long-term outcome of citrin deficiency: report from a nationwide study in Japan. J Inherit Metab Dis. 2022;45(3):431\u201344.","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"719_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/biom10081100","volume":"10","author":"T Saheki","year":"2020","unstructured":"Saheki T, Moriyama M, Funahashi A, Kuroda E. AGC2 (citrin) deficiency-from recognition of the disease till construction of therapeutic procedures. Biomolecules. 2020;10(8):1100. https:\/\/doi.org\/10.3390\/biom10081100.","journal-title":"Biomolecules"},{"issue":"3","key":"719_CR11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2012.09.016","volume":"107","author":"SCS Nagamani","year":"2012","unstructured":"Nagamani SCS, Shchelochkov OA, Mullins MA, Carter S, Lanpher BC, Sun Q, et al. A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. Mol Genet Metab. 2012;107(3):315\u201321.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"719_CR12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ajhg.2012.03.018","volume":"90","author":"SCS Nagamani","year":"2012","unstructured":"Nagamani SCS, Campeau PM, Shchelochkov OA, Premkumar MH, Guse K, Brunetti-Pierri N, et al. Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. Am J Hum Genet. 2012;90(5):836\u201346.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"719_CR13","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1007\/s10072-025-08153-3","volume":"46","author":"A Burlina","year":"2025","unstructured":"Burlina A, Ardissone A, Battini R, Burlina A, Gasperini S, Pession A, et al. Arginase 1 deficiency: a treatable form of spastic paraplegia. Neurol Sci. 2025;46(9):4219\u201328.","journal-title":"Neurol Sci"},{"issue":"3","key":"719_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/jnc.15774","volume":"165","author":"P Meera","year":"2023","unstructured":"Meera P, Uusi-Oukari M, Wallner M, Lipshutz GS. Guanidinoacetate (GAA) is a potent GABA(A) receptor GABA mimetic: implications for neurological disease pathology. J Neurochem. 2023;165(3):445\u201354.","journal-title":"J Neurochem"},{"key":"719_CR15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fneur.2019.00131","volume":"10","author":"E Panza","year":"2019","unstructured":"Panza E, Martinelli D, Magini P, Dionisi Vici C, Seri M. Hereditary spastic paraplegia is a common phenotypic finding in ARG1 deficiency, P5CS deficiency and HHH syndrome: three inborn errors of metabolism caused by alteration of an interconnected pathway of glutamate and urea cycle metabolism. Front Neurol. 2019;10:131.","journal-title":"Front Neurol"},{"issue":"6","key":"719_CR16","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/jimd.12100","volume":"42","author":"J Haberle","year":"2019","unstructured":"Haberle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192\u2013230.","journal-title":"J Inherit Metab Dis"},{"key":"719_CR17","volume-title":"GeneReviews\u00ae","author":"N Ah Mew","year":"1993","unstructured":"Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML, et al. Urea cycle disorders overview. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews\u00ae. Seattle: University of Washington; 1993."},{"issue":"3","key":"719_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijns8030041","volume":"8","author":"MS Watson","year":"2022","unstructured":"Watson MS, Lloyd-Puryear MA, Howell RR. The progress and future of US newborn screening. Int J Neonatal Screen. 2022;8(3):41. https:\/\/doi.org\/10.3390\/ijns8030041.","journal-title":"Int J Neonatal Screen"},{"key":"719_CR19","volume":"27","author":"Y Huang","year":"2021","unstructured":"Huang Y, Sharma R, Feigenbaum A, Lee C, Sahai I, Sanchez Russo R, et al. Arginine to ornithine ratio as a diagnostic marker in patients with positive newborn screening for hyperargininemia. Mol Genet Metab Rep. 2021;27:100735.","journal-title":"Mol Genet Metab Rep."},{"issue":"4","key":"719_CR20","doi-asserted-by":"crossref","DOI":"10.3390\/ijns6040077","volume":"6","author":"T Vasquez-Loarte","year":"2020","unstructured":"Vasquez-Loarte T, Thompson JD, Merritt JL. Considering proximal urea cycle disorders in expanded newborn screening. Int J Neonatal Screen. 2020;6(4):77.","journal-title":"Int J Neonatal Screen"},{"key":"719_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-3-030-94510-7","volume-title":"Nutrition management of inherited metabolic diseases: lessons from metabolic university","author":"E Macleod","year":"2022","unstructured":"Macleod E. Nutrition management of urea cycle disorder. In: Bernstein LE, Rohr F, van Calcar S, editors. Nutrition management of inherited metabolic diseases: lessons from metabolic university. 2nd ed. Springer; 2022. p. 225\u201340. https:\/\/doi.org\/10.1007\/978-3-030-94510-7.","edition":"2"},{"issue":"1","key":"719_CR22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jimd.12294","volume":"44","author":"K Hayasaka","year":"2021","unstructured":"Hayasaka K. Metabolic basis and treatment of citrin deficiency. J Inherit Metab Dis. 2021;44(1):110\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"719_CR23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-9258(18)88359-4","volume":"17","author":"HB Lewis","year":"1914","unstructured":"Lewis HB. Studies in the synthesis of hippuric acid in the animal organism. J Biol Chem. 1914;17:225\u201331.","journal-title":"J Biol Chem"},{"key":"719_CR24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0021-9258(18)87245-3","volume":"17","author":"CP Sherwin","year":"1919","unstructured":"Sherwin CP, Sellers-Kennard K. Toxicity of phenylacetic acid. J Biol Chem. 1919;17:259\u201364.","journal-title":"J Biol Chem"},{"issue":"23","key":"719_CR25","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJM198406073102304","volume":"310","author":"M Msall","year":"1984","unstructured":"Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med. 1984;310(23):1500\u20135.","journal-title":"N Engl J Med"},{"issue":"1","key":"719_CR26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/jlb\/lsv060","volume":"3","author":"M Herder","year":"2016","unstructured":"Herder M. Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada. J Law Biosci. 2016;3(1):158\u201366.","journal-title":"J Law Biosci"},{"key":"719_CR27","first-page":"435","volume-title":"Inherited metabolic disorders","author":"GF Hoffmann","year":"2002","unstructured":"Hoffmann GF, Nyhan WL, Zschocke J, Kahler SG, Mayatepek E. Inherited metabolic disorders. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 435."},{"issue":"12","key":"719_CR28","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1002\/1097-0142(19950615)75:12<2932::AID-CNCR2820751221>3.0.CO;2-P","volume":"75","author":"A Thibault","year":"1995","unstructured":"Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 1995;75(12):2932\u20138.","journal-title":"Cancer"},{"issue":"7","key":"719_CR29","first-page":"1690","volume":"54","author":"A Thibault","year":"1994","unstructured":"Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 1994;54(7):1690\u20134.","journal-title":"Cancer Res"},{"issue":"2","key":"719_CR30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1005661631281","volume":"23","author":"V Praphanphoj","year":"2000","unstructured":"Praphanphoj V, Boyadjiev SA, Waber LJ, Brusilow SW, Geraghty MT. Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia. J Inherit Metab Dis. 2000;23(2):129\u201336.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"719_CR31","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.23589","volume":"51","author":"BM McGuire","year":"2010","unstructured":"McGuire BM, Zupanets IA, Lowe ME, Xiao X, Syplyviy VA, Monteleone J, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology. 2010;51(6):2077\u201385.","journal-title":"Hepatology"},{"issue":"3","key":"719_CR32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ymgme.2018.09.001","volume":"125","author":"SA Berry","year":"2018","unstructured":"Berry SA, Vockley J, Vinks AA, Dong M, Diaz GA, McCandless SE, et al. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders. Mol Genet Metab. 2018;125(3):251\u20137.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"719_CR33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymgme.2013.09.017","volume":"110","author":"M Mokhtarani","year":"2013","unstructured":"Mokhtarani M, Diaz GA, Rhead W, Berry SA, Lichter-Konecki U, Feigenbaum A, et al. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol Genet Metab. 2013;110(4):446\u201353.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"719_CR34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107699","volume":"140","author":"KE Glinton","year":"2023","unstructured":"Glinton KE, Minard CG, Liu N, Sun Q, Elsea SH, Burrage LC, et al. Monitoring the treatment of urea cycle disorders using phenylbutyrate metabolite analyses: still many lessons to learn. Mol Genet Metab. 2023;140(3):107699.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"719_CR35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ymgme.2017.08.011","volume":"122","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Almannai M, Sutton VR, Sun Q, Elsea SH. Quantitation of phenylbutyrate metabolites by UPLC-MS\/MS demonstrates inverse correlation of phenylacetate:phenylacetylglutamine ratio with plasma glutamine levels. Mol Genet Metab. 2017;122(3):39\u201345.","journal-title":"Mol Genet Metab"},{"key":"719_CR36","doi-asserted-by":"crossref","DOI":"10.25302\/12.20.CER.150227816","volume-title":"Comparing treatment options for urea cycle disorders","author":"N Ah Mew","year":"2020","unstructured":"Ah Mew N, McCarter R, Izem R, Markus A, Gerstein M, Rice K, et al. Comparing treatment options for urea cycle disorders. Washington, DC: Patient-Centered Outcomes Research Institute (PCORI); 2020."},{"issue":"4","key":"719_CR37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ymgme.2014.01.006","volume":"111","author":"G Mazariegos","year":"2014","unstructured":"Mazariegos G, Shneider B, Burton B, Fox IJ, Hadzic N, Kishnani P, et al. Liver transplantation for pediatric metabolic disease. Mol Genet Metab. 2014;111(4):418\u201327.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"719_CR38","doi-asserted-by":"crossref","first-page":"108112","DOI":"10.1016\/j.ymgme.2023.108112","volume":"141","author":"R Posset","year":"2024","unstructured":"Posset R, Garbade SF, Gleich F, Nagamani SCS, Gropman AL, Epp F, et al. Impact of supplementation with L-citrulline\/arginine after liver transplantation in individuals with urea cycle disorders. Mol Genet Metab. 2024;141(3):108112.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"719_CR39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0021-9258(18)66077-6","volume":"204","author":"S Grisolia","year":"1953","unstructured":"Grisolia S, Cohen PP. Catalytic role of of glutamate derivatives in citrulline biosynthesis. J Biol Chem. 1953;204(2):753\u20137.","journal-title":"J Biol Chem"},{"issue":"2","key":"719_CR40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0021-9258(18)55511-3","volume":"198","author":"S Grisolia","year":"1952","unstructured":"Grisolia S, Cohen PP. The catalytic role of carbamyl glutamate in citrulline biosynthesis. J Biol Chem. 1952;198(2):561\u201371.","journal-title":"J Biol Chem"},{"issue":"2","key":"719_CR41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1203\/PDR.0b013e318179454b","volume":"64","author":"M Tuchman","year":"2008","unstructured":"Tuchman M, Caldovic L, Daikhin Y, Horyn O, Nissim I, Nissim I, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res. 2008;64(2):213\u20137.","journal-title":"Pediatr Res"},{"key":"719_CR42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/TACG.S12702","volume":"4","author":"N Ah Mew","year":"2011","unstructured":"Ah Mew N, Caldovic L. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. Appl Clin Genet. 2011;4:127\u201335.","journal-title":"Appl Clin Genet"},{"issue":"3\u20134","key":"719_CR43","first-page":"157","volume":"3","author":"N Ah Mew","year":"2018","unstructured":"Ah Mew N, Cnaan A, McCarter R, Choi H, Glass P, Rice K, et al. Conducting an investigator-initiated randomized double-blinded intervention trial in acute decompensation of inborn errors of metabolism: lessons from the N-carbamylglutamate consortium. Transl Sci Rare Dis. 2018;3(3\u20134):157\u201370.","journal-title":"Transl Sci Rare Dis"},{"issue":"1","key":"719_CR44","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1542\/peds.2010-0008","volume":"126","author":"N Ah Mew","year":"2010","unstructured":"Ah Mew N, McCarter R, Daikhin Y, Nissim I, Yudkoff M, Tuchman M. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics. 2010;126(1):208.","journal-title":"Pediatrics"},{"issue":"4","key":"719_CR45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymgme.2013.05.014","volume":"109","author":"U Lichter-Konecki","year":"2013","unstructured":"Lichter-Konecki U, Nadkarni V, Moudgil A, Cook N, Poeschl J, Meyer MT, et al. Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias. Mol Genet Metab. 2013;109(4):354\u20139.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"719_CR46","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/nm.3400","volume":"19","author":"V Rangroo Thrane","year":"2013","unstructured":"Rangroo Thrane V, Thrane AS, Wang F, Cotrina ML, Smith NA, Chen M, et al. Ammonia triggers neuronal disinhibition and seizures by impairing astrocyte potassium buffering. Nat Med. 2013;19(12):1643\u20138.","journal-title":"Nat Med"},{"issue":"8","key":"719_CR47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41581-020-0267-8","volume":"16","author":"R Raina","year":"2020","unstructured":"Raina R, Bedoyan JK, Lichter-Konecki U, Jouvet P, Picca S, Mew NA, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. Nat Rev Nephrol. 2020;16(8):471\u201382.","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"719_CR48","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/nm.2544","volume":"17","author":"A Erez","year":"2011","unstructured":"Erez A, Nagamani SCS, Shchelochkov OA, Premkumar MH, Campeau PM, Chen Y, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med. 2011;17(12):1619\u201326.","journal-title":"Nat Med"},{"key":"719_CR49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2019.12.005","volume":"217","author":"G Agnello","year":"2020","unstructured":"Agnello G, Alters SE, Rowlinson SW. Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1. Transl Res. 2020;217:11\u201322.","journal-title":"Transl Res"},{"key":"719_CR50","doi-asserted-by":"crossref","first-page":"102405","DOI":"10.1016\/j.eclinm.2023.102405","volume":"68","author":"RS Russo","year":"2024","unstructured":"Russo RS, Gasperini S, Bubb G, Neuman L, Sloan LS, Diaz GA, et al. Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. EClinicalMedicine. 2024;68:102405.","journal-title":"EClinicalMedicine."},{"issue":"Suppl. 1","key":"719_CR51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1005369926784","volume":"21","author":"SE Raper","year":"1998","unstructured":"Raper SE, Wilson JM, Yudkoff M, Robinson MB, Ye X, Batshaw ML. Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J Inherit Metab Dis. 1998;21(Suppl. 1):119\u201337.","journal-title":"J Inherit Metab Dis"},{"key":"719_CR52","doi-asserted-by":"publisher","unstructured":"Harding C, Thomas J, Breilyn M, Couce M, Geberhiwot T, Guffon N, et al. P171: Durable efficacy and safety of DTX301: Long-term follow up of a phase 1\/2 trial in adults with ornithine transcarbamylase deficiency. Genetics Medicine Open. 2025; 3(Suppl2):13. https:\/\/doi.org\/10.1016\/j.gimo.2025.102136.","DOI":"10.1016\/j.gimo.2025.102136"},{"issue":"3","key":"719_CR53","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3469","volume":"34","author":"Y Yang","year":"2016","unstructured":"Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34(3):334\u20138.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"719_CR54","volume":"6","author":"L Wang","year":"2020","unstructured":"Wang L, Yang Y, Breton C, Bell P, Li M, Zhang J, et al. A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. Sci Adv. 2020;6(7):eaax5701.","journal-title":"Sci Adv"},{"issue":"22","key":"719_CR55","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025;392(22):2235\u201343.","journal-title":"N Engl J Med"},{"issue":"3","key":"719_CR56","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ymthe.2025.01.010","volume":"33","author":"J Zhou","year":"2025","unstructured":"Zhou J, Liang S, Yin L, Frassetto A, Graham A, White R, et al. Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency. Mol Ther. 2025;33(3):1197\u2013212.","journal-title":"Mol Ther"},{"issue":"6","key":"719_CR57","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/jimd.12807","volume":"47","author":"E Richard","year":"2024","unstructured":"Richard E, Martinez-Pizarro A, Desviat LR. Exploring RNA therapeutics for urea cycle disorders. J Inherit Metab Dis. 2024;47(6):1269\u201377.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"719_CR58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2025.02.007","volume":"83","author":"JR Ow","year":"2025","unstructured":"Ow JR, Imagawa E, Chen F, Cher WY, Chan SYT, Gurrampati RR, et al. Developing splice-switching oligonucleotides for urea cycle disorder using an integrated diagnostic and therapeutic platform. J Hepatol. 2025;83(2):411\u201325.","journal-title":"J Hepatol"},{"issue":"6","key":"719_CR59","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jimd.12146","volume":"42","author":"SE Waisbren","year":"2019","unstructured":"Waisbren SE, Stefanatos AK, Kok TMY, Ozturk-Hismi B. Neuropsychological attributes of urea cycle disorders: a systematic review of the literature. J Inherit Metab Dis. 2019;42(6):1176\u201391.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"719_CR60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107696","volume":"140","author":"CN Murali","year":"2023","unstructured":"Murali CN, Barber JR, McCarter R, Zhang A, Gallant N, Simpson K, et al. Health-related quality of life in a systematically assessed cohort of children and adults with urea cycle disorders. Mol Genet Metab. 2023;140(3):107696.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"719_CR61","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.101039","volume":"26","author":"R Posset","year":"2024","unstructured":"Posset R, Garbade SF, Gleich F, Scharre S, Okun JG, Gropman AL, et al. Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders. Genet Med. 2024;26(4):101039.","journal-title":"Genet Med"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00719-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:29:17Z","timestamp":1760714957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00719-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00719-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Uta Lichter-Konecki has no conflicts of interest that are relevant to the content of this article. Nicholas Ah Mew is a medical advisor to the National Urea Cycle Disorders Foundation and Citrin Foundation, serves on the Data Safety Monitoring Board of clinical trials conducted by iECURE and Arcturus Therapeutics, and is a consultant to Ultragenyx Pharmaceutical and Moderna.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"ULK and NA contributed equally to both drafting and editing the manuscript. ULK and NA read and approved the final version of the manuscript, and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}